ITeos nabs $125M as they prep Keytruda combination trial — if Covid-19 will let them
For iTeos, it turned out, $75 million could only last so long.
Two years after announcing their eye-catching Series B raise, the Belgian biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
